Human pharmacokinetic profiling of the dipeptidyl peptidase‐IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling

By  

Biopharmaceutics And Drug Disposition, Vol. 36, Iss. 3, 2015-04 ,pp. : 148-162

John Wiley & Sons Inc

Access to resources Recommend Favorite

The hedgehog pathway inhibitor GDC-0449 shows potential in skin and other cancers

By Doggrell Sheila A  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 3, 2010-03 ,pp. : 451-454

Informa Healthcare

Access to resources Recommend Favorite

The Absolute Oral Bioavailability and Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy Volunteers

By He Yan-Ling  

Clinical Pharmacokinetics, Vol. 46, Iss. 9, 2007-01 ,pp. : 787-802

Adis International

Access to resources Recommend Favorite

A Mechanism-Based Population Pharmacokinetic Model for Characterizing Time-Dependent Pharmacokinetics of Midostaurin and its Metabolites in Human Subjects

By Yin Ophelia Q.P.   Wang Yanfeng   Schran Horst  

Clinical Pharmacokinetics, Vol. 47, Iss. 12, 2008-01 ,pp. : 807-816

Adis International

Access to resources Recommend Favorite

A Semi-Physiological Population Pharmacokinetic Model Describing the Non-linear Disposition of Indisulam

By Zandvliet Anthe   Schellens Jan   Copalu William   Beijnen Jos   Huitema Alwin  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 33, Iss. 5, 2006-10 ,pp. : 543-570

Springer Publishing Company

Access to resources Recommend Favorite